Drug
TD-6450
TD-6450 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
50%
Ph phase_1
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
TD-6450 MAD Study in HCV Infected Subjects
NCT02116543
completedphase_1
TD-6450 SAD and MAD in Healthy Subjects
NCT02022306
completedphase_2
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
NCT02716428
completedphase_2
A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
NCT02593162
Clinical Trials (4)
Showing 4 of 4 trials
NCT02116543Phase 1
TD-6450 MAD Study in HCV Infected Subjects
NCT02022306Phase 1
TD-6450 SAD and MAD in Healthy Subjects
NCT02716428Phase 2
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
NCT02593162Phase 2
A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4